Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...
Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results